Investigational drug · Phase 2
BTV100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dry Eye.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "BTV100"
First trial start
2024
Dec 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BTV100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye
Approved drugs for the same conditions: Dry eye disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "BTV100" as an intervention, largest first.
- Evaluation of BTV100 in Subjects With Dry Eye DiseasePivotal-lookingCompleted
BioTheraVision, Inc.Industry
NCT06543303 · 123 participants · Start Dec 31, 2024 · Primary completion Jan 14, 2026
Drug: BTV100 Low dose; BTV100 Mid dose and 2 more · For: Dry Eye
Sites: Doncaster East, Australia; Sydney, Australia; Kaohsiung City, Taiwan · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer.
DiBiase SJ, Hosseinzadeh K, Gullapalli RP, et al. · Int J Radiat Oncol Biol Phys 2002
Also in development for Dry Eye
- CAM-101Elate Ocular, FD hPLPhase 31 trial
Cambium Bio Limited · Dry Eye Disease, Dry Eye, Dry Eyes Chronic
- SJP-0132Phase 31 trial
Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. · Dry Eye
- VVN001Phase 31 trial
VivaVision Biotech, Inc · Dry Eye
- 0.25% RCI001RCI001Phase 22 trials
ORA, Inc. · Dry Eye Disease (DED), Dry Eye
- TTAX03Phase 22 trials
BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- VSJ-110Phase 21 trial
Vanda Pharmaceuticals · Dry Eye
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.